Elizabeth A. Mullen MD
Assistant Professor of Pediatrics, Dana-Farber Cancer Institute
Join to View Full Profile
450 Brookline AvenueBoston, MA 02215
Phone+1 617-632-1938
Fax+1 617-632-4811
Dr. Mullen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Elizabeth Mullen is a Pediatric Hematologist and Oncologist based in Boston, MA. She earned her medical degree from Yale School of Medicine in 1992 and completed her residency and fellowship in Pediatrics and Pediatric Hematology/Oncology at Boston Children’s Hospital/Boston Medical Center. Dr. Mullen has contributed to research on kidney tumors in children, with several publications in notable journals such as Pediatric Blood & Cancer and Nature Reviews. Urology. Her work includes studies on Wilms tumor and rhabdoid tumors, exploring clinical outcomes and biomarkers associated with these conditions. She has also been involved in clinical trials related to the treatment of Wilms' Tumor.
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1995 - 1998- Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1992 - 1995
Yale School of MedicineClass of 1992
Certifications & Licensure
ME State Medical License 2022 - 2027
CT State Medical License 2022 - 2026
MA State Medical License 1995 - 2026
VT State Medical License 2023 - 2026
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Start of enrollment: 2006 Nov 06
- Studying Biomarkers in Samples From Young Patients With Rhabdoid Tumors Start of enrollment: 2012 Mar 01
- Biomarkers in Urine Samples From Patients With Wilms Tumor Start of enrollment: 2012 Mar 01
Publications & Presentations
PubMed
- Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533.David B Dix, Geetika Khanna, Lindsay A Renfro, Ian C Tfirn, Ethan A Smith
Journal of Clinical Oncology. 2025-11-12 - Updated favourable-histology Wilms tumour risk stratification: rationale for future Children's Oncology Group clinical trials.Daniel J Benedetti, Nicholas G Cost, Peter F Ehrlich, Nicholas Evageliou, Elizabeth Fialkowski
Nature Reviews. Urology. 2025-11-01 - 1 citationsAnti-Tumor Activity of Paclitaxel-Containing Regimens in Recurrent/Refractory Wilms Tumor.Alissa Groisser, Amy Frantz, James I Geller, Michael V Ortiz, David Walterhouse
Pediatric Blood & Cancer. 2025-10-01
Press Mentions
New NCCN Guidelines Analyze Evidence for Cancer Type Found Almost Exclusively in ChildrenFebruary 17th, 2021
More Than 110 Dana-Farber Affiliated Faculty Named as 2021 Top Doctors in Boston MagazineJanuary 5th, 2021- Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children with Solid TumorsJuly 5th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
